Finance

Lists
CBIO:NASDAQ
Crescent Biopharma Inc
USD 16,43
-1,56%
(-0,26) 1D
USD 16,43
0,00% (0,00)
After hours
Closed: 12 Aug., 16:00:01 GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for CBIO...
Open
USD 16,68
High
USD 16,98
Low
USD 16,10
Mkt. cap
610,27 m
Avg. vol.
343,44 k
Volume
0,00
52-wk high
USD 27,41
52-wk low
USD 8,72
EPS
-USD 7,41
Beta
1,24
Shares outstanding
37,14 m
No. of employees
69
Open
USD 16,68
High
USD 16,98
Low
USD 16,10
Mkt. cap
610,27 m
Avg. vol.
343,44 k
Volume
0,00
52-wk high
USD 27,41
52-wk low
USD 8,72
EPS
-USD 7,41
Beta
1,24
Shares outstanding
37,14 m
No. of employees
69
News stories
From web sources and news partners
About Crescent Biopharma Inc
CEO-
Employees69
Founded2024
HeadquartersWaltham, Massachusetts, Verenigde State van Amerika
Sector-
Websitecrescentbiopharma.com
Analyst ratings
Based on 5 analysts giving stock ratings to CBIO in the past 3 months
Strong buy
Buy
4
Hold
1
Sell
0
12-month forecast
Based on 5 Wall Street analysts offering 12 month price targets for CBIO in the last 3 months.
Highest
Current USD 16,43
USD 35,00 (+113,02%)
Average
USD 29,50 (+79,55%)
Lowest
USD 27,00 (+64,33%)
Analyst
Recommendation
Action
Price target
Projected
Date
Robert Driscoll
Wedbush
Buy
Maintained
USD 27,00
+64,3%
07/31/2026
Unknown Analyst
Wedbush
Buy
Maintained
USD 27,00
+64,3%
07/31/2026
Mitchell Kapoor
H.C. Wainwright
Hold
Reiterated
-
-
07/31/2026
Stephen Willey
Stifel Nicolaus
Buy
Maintained
USD 28,00
+70,4%
07/31/2026
Charles Zhu
LifeSci Capital
Buy
Maintained
USD 28,00
+70,4%
07/30/2026
Biren Amin
Piper Sandler
Buy
Maintained
USD 35,00
+113%
06/23/2026
Bradley Canino
Guggenheim
Buy
Maintained
USD 35,00
+113%
04/29/2026
Phil Nadeau
TD Cowen
Buy
Maintained
-
-
04/29/2026
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Sep. 2025
Des. 2025
Mrt. 2026
Jun. 2026
Revenue
-
10,84 m
1,04 m
-
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
20,35 m
95,03 m
17,90 m
19,39 m
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
5,54 m
7,31 m
7,86 m
8,74 m
Operating expense
25,88 m
102,34 m
25,77 m
28,13 m
Total operating expenses
25,88 m
102,34 m
25,77 m
28,13 m
Operating income
-25,88 m
-91,49 m
-24,73 m
-28,13 m
Other non operating income
-
-
-
-
EBT including unusual items
-24,61 m
-90,40 m
-23,28 m
-24,84 m
EBT excluding unusual items
-24,61 m
-90,40 m
-23,28 m
-26,61 m
Income tax expense
-
2,00 m
-
-
Effective tax rate
-
-2,21%
-
-
Other operating expenses
-
-
-
-
Net income
-24,61 m
-92,40 m
-23,28 m
-24,84 m
Net profit margin
-
-852,06%
-2 240,90%
-
Earnings per share
-1,37
-4,92
-0,70
-0,62
Interest and investment income
1,28 m
1,10 m
1,45 m
1,53 m
Interest expense
-
-
-
-
Net interest expenses
1,28 m
1,10 m
1,45 m
1,53 m
Depreciation and amortization charges
-
-
-
-
EBITDA
-25,86 m
-91,44 m
-24,66 m
-28,07 m
Gain or loss from assets sale
-
-
-
-1,77 m
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

What's on your mind?
What's going on with the markets today?
Explore what’s possible
Create a portfolio
Create a task
Deep Search
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google-programme